BPC June 25 update

Small cap COVID vaccine stocks march on - VXRT +96% INO +31%

Price and Volume Movers

Small-cap COVID stocks continued to attract attention with Vaxart, Inc. (NASDAQ: VXRT) shares closing up 96% to $6.26 following its announcement that it signed a Memorandum of Understanding with Attwill Medical Solutions Sterilflow (AMS) as a resource for large scale manufacturing including tableting and enteric coating for Vaxart's oral COVID-19 vaccine, slated to commence a Phase 1 trial this summer.

INOVIO (NASDAQ:INO) shares closed up 31% to $31.25. The company has guided that initial data from their Phase 1 trial of its COVID-19 vaccine, INO-4800, are due for release this month. A Phase 2/3 efficacy trial is planned to begin this summer (July/August).

uniQure N.V. (NASDAQ:QURE) shares fell sharply, closing down 22% to $49.22 on news released late-Wednesday of a license agreement with CSL Behring for rights to etranacogene dezaparvovec, its gene therapy for patients with hemophilia B, diminishing hopes of a buyout of the company.

Xeris Pharmaceuticals, Inc. (NASDAQ:XERS) recorded the largest fall of the five biotech companies that announced stock offerings after hours Wednesday. Shares fell 49% to $2.72.

Athersys, Inc. (NASDAQ:ATHX) shares closed up 30% to $2.88. Analysts at Bank of America initiated coverage of the company with a Buy rating and a price target of $5.

-

Major price movers (stocks priced > $1.00, volume > 50k):

Refer to the BioPharmCatalyst Biotech Stocks page for Top 10 Gainers/Losers/Unusual Volume:

ADVANCERS:

Aptevo Therapeutics Inc. (APVO): $8.96; +56%.

Kitov Pharma Ltd (KTOV): $1.26; +46%.

Citius Pharmaceuticals, Inc. (CTXR): $1.08; +24%.

CytoDyn Inc. (CYDY): $6.15; +23%.

Cardiff Oncology, Inc. (CRDF): $5.10; +23%.

DECLINERS:

Magenta Therapeutics, Inc. (MGTA): $8.31; -14%.

NovaBay Pharmaceuticals, Inc. (NBY): $1.06; -14%.

Progenity, Inc. (PROG): $10.50; -9%.

NantKwest, Inc. (NK): $11.12; -8%.

Atreca, Inc. (BCEL): $21.48; -8%.

Pipeline updates below:

Pipeline Database Updates

Drug Stage Catalyst Market Cap

ASMB – Assembly Biosciences Inc.
ABI-H2158
Hepatitis B virus (HBV)

Phase 1b Phase 1b higher dose cohort data due at EASL August 27-29, 2020. Phase 2 trial initiation announced June 25, 2020.
$758.5 million

CLSN – Celsion Corporation
ThermoDox - OPTIMA
Hepatocellular carcinoma - liver cancer

Phase 3 Phase 3 second analysis due following IDMC meeting first half of July 2020. Final readout 1Q 2021.
$141.5 million

CNSP – CNS Pharmaceuticals Inc.
Berubicin
Glioblastoma

Phase 2 Phase 2 trial planned for 4Q 2020.
$34.1 million

INCY – Incyte Corporation
Pelareorep and retifanlimab (INCMGA00012) - IRENE
Triple-negative breast cancer.

Phase 2 Phase 2 trial to be initiated.
$23.1 billion

TBPH – Theravance Biopharma Inc.
TD-0903
Acute Lung Injury (ALI) caused by COVID-19

Phase 2 Phase 2 commencement of dosing announced June 25, 2020.
$1.3 billion